RT Journal Article SR Electronic T1 Safety and Efficacy of Carbon-ion Radiotherapy Alone for Stage III Non-small Cell Lung Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 379 OP 386 DO 10.21873/anticanres.13963 VO 40 IS 1 A1 MAKOTO ANZAI A1 NAOYOSHI YAMAMOTO A1 KAZUHIKO HAYASHI A1 MIO NAKAJIMA A1 AKIHIRO NOMOTO A1 KAZUHIKO OGAWA A1 HIROSHI TSUJI YR 2020 UL http://ar.iiarjournals.org/content/40/1/379.abstract AB Background/Aim: We evaluated the efficacy and safety of carbon-ion radiotherapy (CIRT) alone for Stage III non-small-cell lung cancer (NSCLC). Patients and Methods: Data of 65 patients (median age=73 years) with Stage III NSCLC who underwent CIRT alone in the QST Hospital, Chiba, Japan, between 1997 and 2015 were retrospectively analysed. The median dose was 72.0 Gy (relative biological effectiveness). Results: The median follow-up was 27.6 months (range=1.6-207.7 months). Two-year local control, progression-free survival (PFS), and overall survival (OS) rates were 73.9%, 38.6%, and 54.9%, respectively. Overall, 1 (2%), 4 (6%), and 1 (2%) patient developed Grade 4 (mediastinal haemorrhage), Grade 3 (radiation pneumonitis), and Grade 3 (bronchial fistula) toxicities, respectively. On univariate analysis, clinical T and N stage and CIRT timing were significant predictors of PFS and OS; clinical target volume was a significant predictor of PFS. Conclusion: CIRT alone is effective with acceptable toxicity for Stage III NSCLC.